Press coverage about iCo Therapeutics (OTCMKTS:ICOTF) has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCo Therapeutics earned a coverage optimism score of 1.60 on their scale. InfoTrie also gave headlines about the biotechnology company an news buzz score of 0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near term.

Shares of OTCMKTS ICOTF remained flat at $$0.07 during mid-day trading on Thursday. The stock had a trading volume of 9,800 shares, compared to its average volume of 1,327. iCo Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.13. The business’s 50-day moving average is $0.05 and its 200 day moving average is $0.06.

iCo Therapeutics Company Profile

iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.

Recommended Story: Diversification in Investing

Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with’s FREE daily email newsletter.


- Advertisement -